Immunization

JSI partnered with Haiti’s Ministry of Public Health and Population to improve vaccination coverage by addressing the practical barriers families face. By implementing catch-up and weekend immunization sessions beyond standard clinic hours, we have reached zero-dose and under-vaccinated infants living in urban and remote or logistically difficult geographical areas. Out of a total target population of 12,993 children in JSI-supported municipalities, we reached 10,518 with Penta 1 and 9,950 with Penta 3 (a proxy for routine coverage in the first year of life) despite security challenges.

JSI supports ministries of health in selecting, introducing, and optimizing vaccines to ensure immunization programs remain responsive to evolving country needs. We have assisted more than 30 countries in developing and submitting over 100 Gavi vaccine applications for vaccine introductions and switches across more than eight diseases. In the last 15 years, we have supported over 20 countries in Africa and Asia to prioritize and optimize vaccine introductions and product and schedule switches, including four prioritization workshops in 2023–2025.

Learn more about this work.

With support from the Gates Foundation, JSI leads the HPV Vaccine Acceleration Program Partners Initiative (HAPPI) Consortium. Through technical assistance and implementation research, the consortium has supported over 20 countries with HPV vaccine introduction, product switches, and program improvements, contributing to protection for over 34.1 million girls from cervical cancer. As one of Gavi’s first technical assistance providers for HPV vaccine rollout, we have supported the successful submissions of over 46% of all applications to Gavi for HPV vaccine TA since 2023, 25% of the HPV vaccine new introductions, and 45% of the multi-age cohort campaigns, helping Gavi reach its goal of 86 million girls vaccinated ahead of schedule.

Learn more about the HAPPI Consortium.